During the previous Global Liver Health Forums, HCPs have heard 17 leading international experts and discovered the latest updates in NAFLD research and current clinical practice. All sessions were live streamed with interactive Q&A!

Like to find out more?

Topics that were presented:

  • NAFLD epidemiology and co-morbidities… 
  • Disease burden and therapeutic approach…
  • The value of RWD (real world data) – MANPOWER studies
  • The NAFLD patient journey… 
  • Hepatoprotective treatment options…including the role of Essential Phospholipids (EPL)  
  • NAFLD to MAFLD - the importance of steatosis in the paradigm shift 
  • Detecting steatosis in clinical practice - EPOCH Registry 
  • Essential phospholipids - latest Real World data 
  • Digital trends in healthcare - impact on NAFLD management 
  • NAFLD profiling through physician practice - Polish RESTORE study
  • NAFLD/MAFLD guidelines overview  

Like to find out more?

Replay earlier webinars

3rd Global Liver Health Forum

    Welcome and introduction

    Sanofi
    10:00 – 10:10 (CET)

    SESSION 1 

    Essential Phospholipids

    Prof Dajani

    10:00 – 10:25 (CET)

    Membrane protection against NAFLD & NASH

    Prof An

    10:25 – 10:40 (CET)

    MAFLD & Covid-19

    Prof Sollano

    11:00 – 11:15 (CET)

    Overview the progress of NASH treatment

    Prof Lu

    11:15 – 11:30 (CET)

    Welcome and introduction

    Sanofi
    10:00 – 10:10 (CET)

    SESSION 1 

    Cardiovascular and metabolic risks of MAFLD - implications for clinical practice

    Prof. Hartleb

    10:10 – 10:25 (CET)

    Potential molecular mechanisms of EPL - insights from EASL 2022

    Prof. Fricker

    10:25 – 10:40 (CET)

    Drug-induced liver injury (DILI) - the importance of early detection

    Prof. Mao

    11:00 – 11:15 (CET)

    Global Liver Institute’s Annual Report

    Donna Cryer

    11:15 – 11:25 (CET)

    Welcome and introduction

    Sanofi
    10:00 – 10:05 (UTC+2)

    SESSION 1

    From NAFLD to MAFLD - the importance of steatosis in the paradigm shift

    Prof M Eslam
    10:05 - 10:20 (UTC+2

    Detecting steatosis in clinical practice - insights from the EPOCH

    Prof L Lazebnik
    10:20 - 10:35 (UTC+2)

    Q&A Session
    10:35 - 10:45 (UTC+2)

    Break
    10:45 - 10:55 (UTC+2)

    SESSION 2

    Essential phospholipids - latest evidence reviewed

    Dr A Dajani
    10:55 - 11:10 (UTC+2)

    Digital trends in healthcare - the potential impact on NALFD

    Alexandra Fulford
    11:10 - 11:25 (UTC+2)

    Q&A Session
    11:25 - 11:35 (UTC+2)
     

    Conclusions and closing remarks
    11:35 - 11:40 (UTC+2)

    Welcome and introduction

    Sanofi, Prof Hartelb
    10:00 – 10:10 (UTC+2)

    SESSION 1

    Early diagnostics of NAFLD – spotting warning signs to prevent progression

    Prof N Stefan
    10:10 - 10:25 (UTC+2)

    Healthcare practitioners’ diagnostic and treatment practice patterns of non-alcoholic fatty liver disease in Poland – a real-world evidence study

    Prof M Hartleb
    10:25 - 10:40 (UTC+2)

    Q&A Session
    10:40 - 10:50 (UTC+2)

    Break
    10:50 - 11:00 (UTC+2)

    SESSION 2

    The importance of fast identification and understanding disease progression – key notes for NAFLD management

    Prof C Fierbinteanu
    11:00 - 11:15 (UTC+2)

    Essential phospholipids – efficacy across the spectrum of NAFLD origins

    Prof E Sas
    11:15 - 11:30 (UTC+2)

    Q&A Session
    11:30 - 11:40 (UTC+2)

    Summary and closing remarks
    11:40 - 11:45 (UTC+2)

    Welcome and introduction

    Sanofi, Prof Fan
    10:00 – 10:10 (UTC+2)

    SESSION 1

    Putting MAFLD into perspective – liver-directed hepatoprotective treatment options

    Prof J Fan
    10:10 - 10:25 (UTC+2)

    Hepatic steatosis in MAFLD – importance of early intervention

    Prof C Pavlov
    10:25 - 10:40 (UTC+2)

    Break
    10:40 - 10:45 (UTC+2)

    SESSION 2

    Essential phospholipids – new perspectives on the MoA

    Prof G Fricker
    11:45 - 11:00 (UTC+2)

    REPAIR study insights – essential phospholipids across the liver health continuum

    Prof A Nersesov
    11:00 - 11:15 (UTC+2)

    Break
    11:15 - 11:20 (UTC+2)


    Panel Discussion

    Efforts for early detection and screening of NAFLD, and global burden of NAFLD

    Donna Cryer
    11:20 - 11:30 (UTC+2)

    Discussion

    All Panelist
    11:30 - 12:05 (UTC+2)
     

    Concluding remark

    Donna Cryer
    12:05 - 12:15 (UTC+2)

    Welcome and introduction

    Sanofi
    14:00 – 14:15 (UTC+2)

    Insights into NAFLD burden and epidemiology. What does the data tell us? Global insights

    Prof. Zobair M. Younossi
    14:15 – 14:40 (UTC+2)

    NAFLD and metabolic comorbidities. Current understanding and perspectives

    Prof. Jörn M. Schattenberg
    14:40 – 15:05 (UTC+2)

    Q&A Session
    15:05 – 15:15 (UTC+2)

    Break
    15:15 – 15:45 (UTC+2)

    Therapeutic approaches for NAFLD

    Prof. Marek Hartleb
    15:45 – 16:10 (UTC+2)

    Importance of RWE in understanding the current disease landscape: MANPOWER results put into perspective

    Prof. Chavdar Pavlov
    16:10 – 16:35 (UTC+2)

    Q&A Session 2
    16:35 – 16:45 (UTC+2)

    Conclusion and closing remarks
    16:45 – 17:00 (UTC+2)

    Welcome and introduction

    Sanofi
    10:00 – 10:15 (UTC+2)

    What does a NAFLD patient journey look like? Importance of HR-QoL

    Prof. Huiying Rao
    10:15 – 10:40 (UTC+2)

    Emerging role of hepatoprotective treatment options

    Prof. Jian-Gao Fan
    10:40 – 11:05 (UTC+2)

    Essential phospholipids. Mechanism of action in liver disease explained

    Prof. Boguslaw Okopien
    11:05 – 11:30 (UTC+2)

    Q&A Session 3
    11:30 – 11:40 (UTC+2)

    Break
    11:40 – 12:10 (UTC+2)

    The role of the essential phospholipids in NAFLD continuum

    Dr Asad Izziddin Dajani
    12:10 – 12:35 (UTC+2)

    Panel discussion (including 10 minutes for Q&A session 4)
    12:35 – 13:00 (UTC+2)

    Conclusion and closing remarks
    13:00 – 13:15 (UTC+2)

Speakers

Clinical Practice Resource

Discover a wealth of materials: scientific articles, videos and presentations.

> NAFLD Disease and Diagnosis /EPL evidence / > Information for patients / > Patient cases